Bluebird Bio, Inc. (BLUE)
| Market Cap | 2.30B |
| Revenue (ttm) | 241.67M |
| Net Income (ttm) | -621.89M |
| Shares Out | 67.45M |
| EPS (ttm) | -9.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $34.10 |
| Previous Close | $33.89 |
| Change ($) | 0.21 |
| Change (%) | 0.62% |
| Day's Open | 34.25 |
| Day's Range | 33.30 - 34.37 |
| Day's Volume | 1,249,014 |
| 52-Week Range | 24.24 - 68.39 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the...
We believe that the stock price of bluebird bio (NASDAQ: BLUE), a biotechnology company focused on gene therapies for severe genetic disorders and cancer, looks attractive at current levels of around $3...
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, T...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and...
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to pu...
With the stock down 54% over the past year, will investors be catching a falling knife if they buy now?
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc's (NASDAQ: BLUE) Skysona (elivaldogene autotemcel) new...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopt...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell dise...
bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.
Bluebird (BLUE) delivered earnings and revenue surprises of -0.66% and 19.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational pro...
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities ...
Abecma is on the market.
The competition is starting to heat up, but bluebird is far from finished.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previo...
OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--PsiOxus Therapeutics and bluebird bio, Inc. presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021.
The biotech has had a rough couple of years.
New York, New York--(Newsfile Corp. - April 13, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blu...
Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("...
New York, New York--(Newsfile Corp. - April 13, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, ...
New York, New York--(Newsfile Corp. - April 13, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Co...
New York, New York--(Newsfile Corp. - April 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging...
LOS ANGELES, April 12, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the...
NEW YORK, April 12, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securit...
New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, ...
Los Angeles, California--(Newsfile Corp. - April 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("...
New York, New York--(Newsfile Corp. - April 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of bluebird bio, Inc. (NASDAQ: BLUE) alleging t...
New York, New York--(Newsfile Corp. - April 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...
Los Angeles, California--(Newsfile Corp. - April 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("b...
LOS ANGELES--(BUSINESS WIRE)---- $BLUE #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
New York, New York--(Newsfile Corp. - April 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...
Los Angeles, California--(Newsfile Corp. - April 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("b...
NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its offi...
New York, New York--(Newsfile Corp. - April 4, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and cert...
New York, New York--(Newsfile Corp. - April 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2...
New York, New York--(Newsfile Corp. - April 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blue...
NEW YORK, March 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its off...
New York, New York--(Newsfile Corp. - March 29, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and cer...
Investors reacted positively to a key FDA approval.
Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?
Though these stocks have dropped, upcoming news offers hope for them to rebound.
New York, New York--(Newsfile Corp. - March 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of blu...
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) and certain of its off...
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (C... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2013 |
| Stock Exchange NASDAQ | Ticker Symbol BLUE |
Financial Performance
In 2020, Bluebird Bio's revenue was $250.73 million, an increase of 461.25% compared to the previous year's $44.67 million. Losses were -$618.70 million, -21.65% less than in 2019.
Analyst Forecasts
According to 24 analysts, the average rating for Bluebird Bio stock is "Buy." The 12-month stock price forecast is 49.00, which is an increase of 43.70% from the latest price.